Novartis (NOVN: VX) might have a long heritage in leading antimalarial drug development, but there is a new awareness that it needs to bring forward therapies that treat the disease in a different way, says David Hughes, senior global program head in clinical development at the Swiss pharma giant.
The company’s 1999 launch of Coartem (artemether/lumefantrine), the first fixed-dose Artemisinin-based combination therapy (ACT), signalled the start of a new era of effective treatment.
Since 2001, the Novartis Malaria Initiative has made this treatment available to 750 million people without profit, many of them children, along with the necessary education and health-system strengthening alongside this, saving millions of lives across Africa, in particular.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze